Literature DB >> 1744644

Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism.

M Otsuka1, Y Ichiya, S Hosokawa, Y Kuwabara, T Tahara, T Fukumura, M Kato, K Masuda, I Goto.   

Abstract

Striatal blood flow, glucose metabolism and 18F-Dopa uptake were studied with positron emission tomography (PET) in eight non-demented patients with idiopathic Parkinson's disease and eight with atypical Parkinsonism. Patients with atypical Parkinsonism had no specific cause for the Parkinsonian symptoms and were clinically different from Parkinson's disease with lack of resting tremor and a poor response to dopaminergic drugs. Decreased 18F-Dopa uptake in the putamen was observed in patients with Parkinson's disease and atypical Parkinsonism compared with normal controls. 18F-Dopa uptake in the head of the caudate was also significantly reduced in both conditions but relatively less in Parkinson's disease. Decreased blood flow and glucose metabolism in the striatum associated with a global cerebral decrease were also observed in patients with atypical Parkinsonism compared with controls, while they were preserved in patients with Parkinson's disease, indicating affected neurons not only in the striatum but also in the cerebrum in patients with atypical Parkinsonism compared with patients with Parkinson's disease. The differences in the caudate 18F-Dopa uptake, and blood flow and glucose metabolism in the cerebrum including the striatum between Parkinson's disease and atypical Parkinsonism assessed by PET may be due to the differences in the pathophysiological mechanism between Parkinson's disease and atypical Parkinsonism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1744644      PMCID: PMC1014575          DOI: 10.1136/jnnp.54.10.898

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  18 in total

1.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

Authors:  K L Leenders; A J Palmer; N Quinn; J C Clark; G Firnau; E S Garnett; C Nahmias; T Jones; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

2.  Positron emission tomography in Parkinson's disease: glucose and DOPA metabolism.

Authors:  W R Martin; A J Stoessl; M J Adam; W Ammann; M Bergstrom; R Harrop; A Laihinen; J G Rogers; T J Ruth; C I Sayre
Journal:  Adv Neurol       Date:  1987

3.  A rostrocaudal gradient for aromatic acid decarboxylase in the human striatum.

Authors:  E S Garnett; A E Lang; R Chirakal; G Firnau; C Nahmias
Journal:  Can J Neurol Sci       Date:  1987-08       Impact factor: 2.104

4.  Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration.

Authors:  A G De Volder; J Francart; C Laterre; G Dooms; A Bol; C Michel; A M Goffinet
Journal:  Ann Neurol       Date:  1989-08       Impact factor: 10.422

5.  Design and evaluation of a positron emission tomograph: HEADTOME III.

Authors:  I Kanno; S Miura; S Yamamoto; H Iida; M Murakami; K Takahashi; K Uemura
Journal:  J Comput Assist Tomogr       Date:  1985 Sep-Oct       Impact factor: 1.826

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

7.  Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

Authors:  D J Brooks; V Ibanez; G V Sawle; N Quinn; A J Lees; C J Mathias; R Bannister; C D Marsden; R S Frackowiak
Journal:  Ann Neurol       Date:  1990-10       Impact factor: 10.422

8.  Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography.

Authors:  K L Leenders; R S Frackowiak; A J Lees
Journal:  Brain       Date:  1988-06       Impact factor: 13.501

9.  Striatal dopamine distribution in parkinsonian patients during life.

Authors:  C Nahmias; E S Garnett; G Firnau; A Lang
Journal:  J Neurol Sci       Date:  1985-07       Impact factor: 3.181

10.  Cerebral blood flow, oxygen and glucose metabolism with PET in progressive supranuclear palsy.

Authors:  M Otsuka; Y Ichiya; Y Kuwabara; Y Miyake; T Tahara; K Masuda; S Hosokawa; I Goto; M Kato; A Ichimiya
Journal:  Ann Nucl Med       Date:  1989-11       Impact factor: 2.668

View more
  8 in total

1.  Neuropsychological, psychiatric, and cerebral perfusion correlates of leukoaraiosis in Alzheimer's disease.

Authors:  S E Starkstein; L Sabe; S Vázquez; G Di Lorenzo; A Martínez; G Petracca; A Tesón; E Chemerinski; R Leiguarda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

2.  Positron emission tomography neuroimaging in Parkinson's disease.

Authors:  Clare Loane; Marios Politis
Journal:  Am J Transl Res       Date:  2011-07-10       Impact factor: 4.060

Review 3.  Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease.

Authors:  Yilong Ma; David Eidelberg
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.488

4.  Mechanisms of unilateral STN-DBS in patients with Parkinson's disease : a PET study.

Authors:  Noritoshi Arai; Fusako Yokochi; Takashi Ohnishi; Toshimitsu Momose; Ryoichi Okiyama; Makoto Taniguchi; Hiroshi Takahashi; Hiroshi Matsuda; Yoshikazu Ugawa
Journal:  J Neurol       Date:  2008-06-20       Impact factor: 4.849

Review 5.  New Imaging Markers for Movement Disorders.

Authors:  Christine Ghadery; Antonio P Strafella
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-03       Impact factor: 5.081

Review 6.  Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.

Authors:  Usman Saeed; Jordana Compagnone; Richard I Aviv; Antonio P Strafella; Sandra E Black; Anthony E Lang; Mario Masellis
Journal:  Transl Neurodegener       Date:  2017-03-28       Impact factor: 8.014

Review 7.  Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes.

Authors:  Usman Saeed; Anthony E Lang; Mario Masellis
Journal:  Front Neurol       Date:  2020-10-15       Impact factor: 4.003

8.  Comparison of 6-[18F]FDOPA PET with Nigrosome 1 detection in patients with parkinsonism.

Authors:  Enrico Michler; Daniel Kaiser; Kiriaki Eleftheriadou; Björn Falkenburger; Jörg Kotzerke; Sebastian Hoberück
Journal:  EJNMMI Res       Date:  2021-02-15       Impact factor: 3.138

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.